OptiNose, Inc. (NASDAQ:OPTN) is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, OPTN to report 3Q20 loss of $ 0.52 per share.
For the full year, analysts anticipate top line of $ 50.68 million, while looking forward to loss of $ 2.16 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 15.40 million ~ $ 15.40 million
Click Here For More Historical Outlooks Of OptiNose, Inc.
Previous Quarter Performance
OptiNose, Inc. reported loss for the second quarter of $ 0.56 per share, from the revenue of $ 10.27 million. The quarterly revenues boosted 56.55 percent compared with the same quarter last year. Wall street analysts are predicting, OPTN to report 2Q20 loss of $ 0.56 per share from revenue of $ 9.74 million. The top line results outshined analysts by $ 0.53 million or 5.44 percent.
Stock Performance
Shares of OptiNose, Inc. traded low $ -0.20 or -5.21 percent on Wednesday, reaching $ 3.55 with volume of 188.10 thousand shares. OptiNose, Inc. has traded high as $ 3.85 and has cracked $ 3.47 on the downward trend
The closing price of $ 3.55, representing a 19.11 % increase from the 52 week low of $ 3.14 and a 67.92 % decrease over the 52 week high of $ 11.66.
The company has a market capital of $ 184.31 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
OptiNose, Inc. will be hosting a conference call at 8:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.optinose.com
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.
